AAPL   321.66 (-1.06%)
MSFT   182.79 (-1.39%)
FB   225.70 (-1.94%)
GOOGL   1,413.03 (-1.97%)
AMZN   2,455.80 (-0.91%)
NVDA   349.47 (-0.37%)
CGC   16.60 (+0.18%)
BABA   217.13 (-0.68%)
MU   50.98 (+4.21%)
GE   7.59 (+2.99%)
TSLA   859.39 (-2.67%)
AMD   52.53 (-0.38%)
T   31.59 (+0.22%)
ACB   14.08 (-1.54%)
F   6.48 (+4.68%)
GILD   77.34 (+3.94%)
DIS   122.91 (+0.60%)
NFLX   411.50 (-2.48%)
BAC   26.51 (+2.00%)
BA   182.65 (+5.48%)
AAPL   321.66 (-1.06%)
MSFT   182.79 (-1.39%)
FB   225.70 (-1.94%)
GOOGL   1,413.03 (-1.97%)
AMZN   2,455.80 (-0.91%)
NVDA   349.47 (-0.37%)
CGC   16.60 (+0.18%)
BABA   217.13 (-0.68%)
MU   50.98 (+4.21%)
GE   7.59 (+2.99%)
TSLA   859.39 (-2.67%)
AMD   52.53 (-0.38%)
T   31.59 (+0.22%)
ACB   14.08 (-1.54%)
F   6.48 (+4.68%)
GILD   77.34 (+3.94%)
DIS   122.91 (+0.60%)
NFLX   411.50 (-2.48%)
BAC   26.51 (+2.00%)
BA   182.65 (+5.48%)
AAPL   321.66 (-1.06%)
MSFT   182.79 (-1.39%)
FB   225.70 (-1.94%)
GOOGL   1,413.03 (-1.97%)
AMZN   2,455.80 (-0.91%)
NVDA   349.47 (-0.37%)
CGC   16.60 (+0.18%)
BABA   217.13 (-0.68%)
MU   50.98 (+4.21%)
GE   7.59 (+2.99%)
TSLA   859.39 (-2.67%)
AMD   52.53 (-0.38%)
T   31.59 (+0.22%)
ACB   14.08 (-1.54%)
F   6.48 (+4.68%)
GILD   77.34 (+3.94%)
DIS   122.91 (+0.60%)
NFLX   411.50 (-2.48%)
BAC   26.51 (+2.00%)
BA   182.65 (+5.48%)
AAPL   321.66 (-1.06%)
MSFT   182.79 (-1.39%)
FB   225.70 (-1.94%)
GOOGL   1,413.03 (-1.97%)
AMZN   2,455.80 (-0.91%)
NVDA   349.47 (-0.37%)
CGC   16.60 (+0.18%)
BABA   217.13 (-0.68%)
MU   50.98 (+4.21%)
GE   7.59 (+2.99%)
TSLA   859.39 (-2.67%)
AMD   52.53 (-0.38%)
T   31.59 (+0.22%)
ACB   14.08 (-1.54%)
F   6.48 (+4.68%)
GILD   77.34 (+3.94%)
DIS   122.91 (+0.60%)
NFLX   411.50 (-2.48%)
BAC   26.51 (+2.00%)
BA   182.65 (+5.48%)
Log in

NASDAQ:IRMDIradimed Stock Price, Forecast & News

$22.91
-0.64 (-2.72 %)
(As of 06/4/2020 03:10 PM ET)
Add
Compare
Today's Range
$22.84
Now: $22.91
$23.37
50-Day Range
$19.48
MA: $20.85
$23.25
52-Week Range
$14.41
Now: $22.91
$28.43
Volume395 shs
Average Volume37,617 shs
Market Capitalization$276.07 million
P/E Ratio29.75
Dividend YieldN/A
Beta1.31
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Read More
Iradimed logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$38.52 million
Cash Flow$0.98 per share
Book Value$4.83 per share

Profitability

Net Income$9.63 million

Miscellaneous

Employees95
Market Cap$276.07 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Iradimed (NASDAQ:IRMD) Frequently Asked Questions

How has Iradimed's stock been impacted by COVID-19 (Coronavirus)?

Iradimed's stock was trading at $22.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IRMD shares have increased by 1.8% and is now trading at $22.91. View which stocks have been most impacted by Coronavirus.

When is Iradimed's next earnings date?

Iradimed is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Iradimed.

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings data on Thursday, April, 30th. The medical equipment provider reported $0.18 EPS for the quarter, beating the consensus estimate of $0.15 by $0.03. The medical equipment provider had revenue of $8.68 million for the quarter, compared to analyst estimates of $8.72 million. Iradimed had a net margin of 24.65% and a return on equity of 17.99%. View Iradimed's earnings history.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed updated its first quarter 2020 IntraDay earnings guidance on Tuesday, April, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.6-8.7 million, compared to the consensus revenue estimate of $10.61 million.

What price target have analysts set for IRMD?

0 analysts have issued 12-month target prices for Iradimed's stock. Their forecasts range from $30.00 to $30.00. On average, they anticipate Iradimed's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price. View analysts' price targets for Iradimed.

Has Iradimed been receiving favorable news coverage?

Press coverage about IRMD stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iradimed earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutIradimed.

Are investors shorting Iradimed?

Iradimed saw a increase in short interest in April. As of April 30th, there was short interest totaling 468,000 shares, an increase of 7.6% from the April 15th total of 434,900 shares. Based on an average daily volume of 48,100 shares, the days-to-cover ratio is currently 9.7 days. Currently, 7.9% of the company's stock are sold short. View Iradimed's Current Options Chain.

Who are some of Iradimed's key competitors?

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Micron Technology (MU), Paypal (PYPL), Crispr Therapeutics (CRSP), IntriCon (IIN), Mastercard (MA), NovaBay Pharmaceuticals (NBY) and NovaBay Pharmaceuticals (NBY).

Who are Iradimed's key executives?

Iradimed's management team includes the following people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 49)
  • Mr. John McCreery, Chief Operating Officer (Age 64)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
  • Mr. Louis Waldman, Controller (Age 64)

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

Who are Iradimed's major shareholders?

Iradimed's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.02%), Russell Investments Group Ltd. (2.57%), Nine Ten Capital Management LLC (2.30%), Ranger Investment Management L.P. (1.95%), Soleus Capital Management L.P. (1.95%) and RK Capital Management LLC (1.75%). Company insiders that own Iradimed stock include Anthony Vuoto, Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View institutional ownership trends for Iradimed.

Which major investors are selling Iradimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Squarepoint Ops LLC, JPMorgan Chase & Co., RK Capital Management LLC, Ranger Investment Management L.P., AQR Capital Management LLC, Cadence Capital Management LLC, and BlackRock Inc.. Company insiders that have sold Iradimed company stock in the last year include Anthony Vuoto, Brent Johnson, Louis S Waldman, Monty K Allen, and Steven M Nardi. View insider buying and selling activity for Iradimed.

Which major investors are buying Iradimed stock?

IRMD stock was acquired by a variety of institutional investors in the last quarter, including Nine Ten Capital Management LLC, Soleus Capital Management L.P., Russell Investments Group Ltd., Morgan Stanley, Globeflex Capital L P, Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, and Alliancebernstein L.P.. View insider buying and selling activity for Iradimed.

How do I buy shares of Iradimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iradimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $22.91.

How big of a company is Iradimed?

Iradimed has a market capitalization of $276.07 million and generates $38.52 million in revenue each year. The medical equipment provider earns $9.63 million in net income (profit) each year or $0.78 on an earnings per share basis. Iradimed employs 95 workers across the globe.

What is Iradimed's official website?

The official website for Iradimed is www.iradimed.com.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.